EC is one of the commonest cancers worldwide, and its incidence is increasing particularly in the developed world. A patient usually presents with suspicious symptoms (typically PMB) and undergoes a range of investigations and treatment before a definitive diagnosis of EC is made (TVS, hysteroscopy and endometrial biopsy, CT/MRI, surgery for diagnosis, treatment and further staging). Biomarkers have the potential to help screening, diagnosing and staging the disease and could complement conventional means. At the moment, biomarker utilisation and research are more relevant in facilitating staging of EC and thus guiding treatment and aiding prognosis. Biomarker utilisation in screening and diagnosis is much less developed.
CITATION STYLE
Galazis, N. (2017). Biomarkers of endometrial cancer. In Biomarkers for Endometriosis: State of the Art (pp. 27–39). Springer International Publishing. https://doi.org/10.1007/978-3-319-59856-7_2
Mendeley helps you to discover research relevant for your work.